International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7874526
Original Article
Estimation of Magnesium Level after 14 Days of Oral Magnesium Therapy in Children with Severe Acute Malnutrition
 ,
 ,
 ,
 ,
 ,
Published
April 28, 2023
Abstract
Background: SAM is defined by WHO weight for height or length < –3 SD or bilateral pitting oedema or MUAC < 11.5 cm for children age group between 6 to 59 months. Aims and Objections: To observe the effect of oral magnesium therapy in children with severe acute malnutrition (SAM) on serum magnesium level. Material and Methods: This study was conducted from 2020 in Department of Pediatrics, Kamla Raja Hospital, G.R.M.C., Gwalior. Study design: Cross sectional observational study Sample size: 117. Study population: 6 to 59 months. Duration of study: 2 years. Statistical analysis: SPSS version 25. Methods: Weight, height and MUAC were measure at the time of admission and after 14 days of oral magnesium therapy. Observation and Results: Children comprises of 117. Out of these 40 (34.2%) children were from 6 months to 12 months, 36 (30.8%) were in age group 13 to 29 months41 (35.04%) from age group 25 to 60 months. Out of 117, 61 (52.1%) were male and 56 (47.9%) were female. Mean weight were 7.02±1.85 kg on admission and increased to 7.44±1.95 kg after 14 days of oral magnesium therapy. Mean height were remained the same. The MUAC was 11.17±0.72 on admission and increased to 11.41 cm after oral therapy. Conclusion: Children were low MUAC, loss of subcutaneous fat, lethargy mental status have higher chances of magnesia while age, gender and edema, skin changes have no relation with serum magnesium.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1534 Views
70 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved